23 November 2020
Selvita to acquire Fidelta from Galapagos
- Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe -
13 November 2020
Selvita reports strong financial results for Q3 2020
12 November 2020
Selvita will participate in the upcoming 5th Medicinal Chemistry & Protein Degradation Summit
19 October 2020
Selvita will participate in the upcoming 26th annual BIO-Europe
01 October 2020
Selvita Research Centre grant application recommended for financing
17 September 2020
Selvita to present at the 20th Annual Biotech in Europe Forum For Global Partnering & Investment
10 September 2020
Selvita reports strong financial results for H1 2020 and a record backlog
03 June 2020
Selvita raised over EUR 20 million in its Follow-On public offer
28 May 2020
The share issue price in Selvita public offering set at PLN 38
26 May 2020
Selvita Extraordinary General Shareholder Meeting decides to proceed with the Follow-On share issue. Initiation of the book-building process on Wednesday, May 27.
26 May 2020
Selvita reports financial results for Q1 2020: dynamic increase in backlog for 2020 and strong position on the market
29 April 2020
Selvita announces its new development strategy for 2020 – 2023
27 April 2020
Selvita and Ardigen will receive funding for the development of an AI-based high-content screening platform
02 April 2020
Selvita's Capabilities In Antiviral Drug Discovery
26 March 2020
Selvita 2019 financial results: accelerated growth, 43 percent increase in commercial revenues and a very solid backlog for 2020
20 March 2020
Update on Selvita current situation and how COVID-19 influences our daily activities
17 March 2020
Selvita at BIO-Europe Spring 2020
13 February 2020
Selvita as an Innovation Partner of the Inaugural European Targeted Protein Degradation Summit
23 January 2020
Selvita to Exhibit at the North American Protein Degradation Congress in San Diego
08 January 2020
Selvita Open Days